These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Inhibition of human immunodeficiency virus 1 replication in vitro by a self-stabilized oligonucleotide with 2'-O-methyl-guanosine-uridine quadruplex motifs. Kuwasaki T, Hatta M, Takeuchi H, Takaku H. J Antimicrob Chemother; 2003 Apr; 51(4):813-9. PubMed ID: 12654739 [Abstract] [Full Text] [Related]
23. PR_b-targeted PEGylated liposomes for prostate cancer therapy. Demirgöz D, Garg A, Kokkoli E. Langmuir; 2008 Dec 02; 24(23):13518-24. PubMed ID: 18954096 [Abstract] [Full Text] [Related]
25. Flying in the face of resistance: antiviral-independent benefit of HIV protease inhibitors on T-cell survival. Vlahakis SR, Bren GD, Algeciras-Schimnich A, Trushin SA, Schnepple DJ, Badley AD. Clin Pharmacol Ther; 2007 Sep 02; 82(3):294-9. PubMed ID: 17361127 [Abstract] [Full Text] [Related]
26. Peptide-poly(L-lysine citramide) conjugates and their in vitro anti-HIV behavior. Couffin-Hoarau AC, Aubertin AM, Boustta M, Schmidt S, Fehrentz JA, Martinez J, Vert M. Biomacromolecules; 2009 Apr 13; 10(4):865-76. PubMed ID: 19296658 [Abstract] [Full Text] [Related]
28. Transfer of antivirals to skin Langerhans cells--a novel approach to anti-HIV treatment by "antiviral peplotion". Becker Y. Acta Biochim Pol; 1996 Apr 13; 43(1):175-81. PubMed ID: 8790722 [Abstract] [Full Text] [Related]
29. Therapeutic strategies towards HIV-1 infection in macrophages. Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S. Antiviral Res; 2006 Sep 13; 71(2-3):293-300. PubMed ID: 16806514 [Abstract] [Full Text] [Related]
30. Blockage of HIV-1 production through inhibition of proviral DNA synthesis by N,O-didecanoyl serinal dimethylacetal. Takamune N, Misumi S, Furuishi K, Shoji S. IUBMB Life; 1999 Sep 13; 48(3):311-5. PubMed ID: 10690644 [Abstract] [Full Text] [Related]
34. Mechanism of inhibition of the human immunodeficiency virus type 1 by the oxygen radical generating agent bleomycin. Georgiou NA, van der Bruggen T, Oudshoorn M, de Bie P, Jansen CA, Nottet HS, Marx JJ, van Asbeck BS. Antiviral Res; 2004 Aug 13; 63(2):97-106. PubMed ID: 15302138 [Abstract] [Full Text] [Related]
35. Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein. Li H, Song H, Heredia A, Le N, Redfield R, Lewis GK, Wang LX. Bioconjug Chem; 2004 Aug 13; 15(4):783-9. PubMed ID: 15264865 [Abstract] [Full Text] [Related]
36. Inhibition of HIV-1 replication in macrophages by a heterodinucleotide of lamivudine and tenofovir. Rossi L, Franchetti P, Pierigé F, Cappellacci L, Serafini S, Balestra E, Perno CF, Grifantini M, Caliò R, Magnani M. J Antimicrob Chemother; 2007 Apr 13; 59(4):666-75. PubMed ID: 17327293 [Abstract] [Full Text] [Related]
37. The role of receptors in the HIV-1 entry process. Jones R, Nelson M. Eur J Med Res; 2007 Oct 15; 12(9):391-6. PubMed ID: 17933719 [Abstract] [Full Text] [Related]
38. Naturally occurring protease inhibitors potent against the human immunodeficiency virus. Noever D. Biochem Biophys Res Commun; 1996 Oct 03; 227(1):125-30. PubMed ID: 8858113 [Abstract] [Full Text] [Related]
40. Non-polymeric nano-carriers in HIV/AIDS drug delivery and targeting. Gupta U, Jain NK. Adv Drug Deliv Rev; 2010 Mar 18; 62(4-5):478-90. PubMed ID: 19913579 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]